These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12796575)

  • 21. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis & antitumor activity of epothilones B and D and their analogs.
    Cheng H; Huang G
    Future Med Chem; 2018 Jun; 10(12):1483-1496. PubMed ID: 29788770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs.
    Benayoun L; Gingis-Velitski S; Voloshin T; Segal E; Segev R; Munster M; Bril R; Satchi-Fainaro R; Scherer SJ; Shaked Y
    Stem Cells; 2012 Sep; 30(9):1831-41. PubMed ID: 22782858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis.
    Stafford SJ; Schwimer J; Anthony CT; Thomson JL; Wang YZ; Woltering EA
    J Surg Res; 2005 May; 125(1):104-8. PubMed ID: 15836858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor angiogenesis and therapy.
    Cao Y
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S340-3. PubMed ID: 16507405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
    Righi M; Giacomini A; Lavazza C; Sia D; Carlo-Stella C; Gianni AM
    Lab Invest; 2009 Sep; 89(9):1063-70. PubMed ID: 19652644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
    Nicoli S; Ribatti D; Cotelli F; Presta M
    Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of VEGF pathways in human physiologic and pathologic angiogenesis.
    Lyons JM; Schwimer JE; Anthony CT; Thomson JL; Cundiff JD; Casey DT; Maccini C; Kucera P; Wang YZ; Boudreaux JP; Woltering EA
    J Surg Res; 2010 Mar; 159(1):517-27. PubMed ID: 19577260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiangiogenic agents and targets: A perspective.
    Teicher BA
    Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
    Di Martile M; Gabellini C; Desideri M; Matraxia M; Farini V; Valentini E; Carradori S; Ercolani C; Buglioni S; Secci D; Andreazzoli M; Del Bufalo D; Trisciuoglio D
    J Exp Clin Cancer Res; 2020 Jun; 39(1):103. PubMed ID: 32498717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy.
    Paez-Ribes M; Man S; Xu P; Kerbel RS
    Clin Cancer Res; 2015 Dec; 21(24):5488-98. PubMed ID: 26169967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a human cardiac tissue-based angiogenesis model.
    Lewis JM; Anthony CT; Harrison LH; Ferguson TB; Andrew Heck H; Rubenstein F; Balster DA; Woltering EA
    J Surg Res; 2006 Sep; 135(1):34-7. PubMed ID: 16603188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent developments in the chemical biology of epothilones.
    Altmann KH
    Curr Pharm Des; 2005; 11(13):1595-613. PubMed ID: 15892665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo.
    Chao WR; Amin K; Shi Y; Hobbs P; Tanabe M; Tanga M; Jong L; Collins N; Peters R; Laderoute K; Dinh D; Yean D; Hou C; Sato B; Alt C; Sambucetti L
    Angiogenesis; 2011 Mar; 14(1):1-16. PubMed ID: 21104121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, anticancer activity and cytotoxicity of galactosylated epothilone B.
    Gao H; Huang G
    Bioorg Med Chem; 2018 Nov; 26(20):5578-5581. PubMed ID: 30318441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antineovascular therapy, a novel antiangiogenic approach.
    Shimizu K; Asai T; Oku N
    Expert Opin Ther Targets; 2005 Feb; 9(1):63-76. PubMed ID: 15757482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.